A Phase 3 interventional study of Dolutegravir 50 mg twice daily and Dolutegravir placebo twice daily in HIV Infections, sponsored by ViiV Healthcare. Completed at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-02.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.
Among the 55 studies testing dolutegravir in HIV Infections, this one is the 46th largest by enrollment, is one of 2 that started in 2012, is one of 21 in phase 3, and was the 10th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in Romania, South Africa, Uganda
José Antonio Mata Marín · Sites in Mexico
Ages 18–70
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+
José Antonio Mata Marín · Sites in Mexico
Ages 18–70 · Men only
ViiV Healthcare · Sites in United States
Ages 6–12
By country, each count listing its studies:
Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 15 · Phase 3 24 · Phase 4 11
First in 2009; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 126 across the 55 interventional studies. Of the 43 that completed or were terminated, 26 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 159th largest by enrollment of the 210 interventional ones that give a count, is one of 3 that started in 2012, is one of 65 in phase 3, and was the 148th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing dolutegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07031063Instituto Mexicano del Seguro SocialSafety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 55 studies testing dolutegravir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
Study ING116529 is a multicenter, randomized, study with an initial 7 day placebo- controlled, functional monotherapy phase to quantify the antiviral activity attributable to dolutegravir (DTG) in HIV-1 infected, ART-experienced adults who are experiencing virological failure on an Integrase inhibitor containing regimen (current RAL or ELV failures), with evidence of genotypic resistance to RAL or ELV at study entry. Thirty subjects will be randomized (1:1) to receive either DTG 50mg BID (Arm A) or Placebo (Arm B) with the current failing regimen for 7 days (RAL or ELV should be discontinued prior to dosing with DTG). At Day 8, subjects from both arms will enter an open label phase and receive open label DTG 50mg BID with an optimized background regimen containing at least one fully active drug.
Study ING116529 is a multicenter, randomized, study with an initial 7 day placebo-controlled, functional monotherapy phase to assess the antiviral activity and safety of a dolutegravir (DTG, GSK1349572) containing regimen in HIV-1 infected, ART-experienced adults with virological failure on an integrase inhibitor (INI) containing regimen.
Subjects must have evidence of genotypic resistance to raltegravir [RAL] or elvitegravir [ELV] at Screening and documented current or historical genotypic or phenotypic resistance to at least two other antiretroviral therapy drug classes.
The study is designed to provide an accurate measure of the intrinsic antiviral activity of DTG 50mg twice daily versus placebo both administered with the current failing regimen in a randomised double-blind phase to Day 8. This will be followed by an open label phase with all subjects receiving DTG 50mg twice daily with an optimized background regimen (containing at least one fully active drug) until subjects no longer derive clinical benefit or until DTG is locally available. Thirty subjects will be randomized (1:1) to receive either DTG 50mg BID (Arm A) or Placebo (Arm B) with the current failing regimen for 7 days (RAL or ELV should be discontinued prior to dosing at Day 1). At Day 8, subjects from both arms will enter an open label phase and receive open label DTG 50mg BID with an optimized background regimen containing at least one fully active drug The primary analysis will be conducted after the last subject enrolled has completed the randomised, double-blind phase at Day 8. Additional analyses may be performed prior to study closure when all ongoing subjects transition to locally available commercial DTG.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive dolutegravir (DTG) 50 milligrams (mg) twice daily (BID) and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the Double-blind (DB) Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
Drug: Dolutegravir 50 mg twice daily
Subjects will receive matching placebo BID and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the DB Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
Drug: Dolutegravir 50 mg twice daily · Drug: Dolutegravir placebo twice daily
Active dolutegravir plus failing background regimen (Day 1 to Day 7). Open label dolutegravir plus optimized background regimen (from Day 8)
Also known as: GSK1349572
Dolutegravir placebo plus failing background regimen (Day 1 to Day 7)
Also known as: GSK1349572 Placebo
Mean Change From Baseline in Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) at Day 8
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1) and Day 8. Change from Baseline was calculated as the value at Day 8 minus the value at Baseline (Day 1). The analysis was performed using statistical modeling correcting for Baseline plasma HIV-1 RNA, Baseline Dolutegravir (DTG) fold change (FC), the overall susceptibility score (OSS) of the failing regimen, and the interaction between DTG FC and treatment. Means and differences were calculated using the average Baseline DTG FC of the entire Intent-to-Treat Exposed (ITT-E) Population. The last observation carried forward with discontinuation equals Baseline (LOCFDB) dataset was used for the analysis. For the LOCFDB dataset, missing values were carried forward from the previous, non-missing, available on-treatment assessment, except formissing values due to premature withdrawal or Day 8 missing values, which had the Baseline value imputed.
Time frame: Baseline and Day 8
Absolute Values in Plasma HIV-1 RNA Over Time
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Day 8, Day 28, Week 8, Week 12, Week 16, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, and Week 84. NA indicates data was not available.
Time frame: Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84
Mean Change From Baseline in Plasma HIV-1 RNA Over Time
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Day 8, Day 28, Week 8, Week 12, Week 16, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, and Week 84. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
Time frame: Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84
Number of Participants With Plasma HIV-1 RNA <50 c/mL Over Time
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1); Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, and 48. Number of participants with plasma HIV-1 RNA level \<50 c/mL was obtained using Food and Drug Administration's (FDA's) snapshot algorithm, where all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) were treated as non-responders. Also, participants who switched their concomitant antiretroviral therapy (ART) prior to the visit of interest as follows were also treated as non-responders: background ART substitutions not permitted per protocol; background ART substitutions permitted per protocol; however, the decision to switch is not documented as being before or at the first On-treatment visit after switching to optimized background regimen (OBR) (i.e. Day 28) where HIV-1 RNA is assessed.
Time frame: Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40 and 48
Number of Participants With Plasma HIV-1 RNA <400 c/mL Over Time
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1); Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40 and 48. Number of participants with plasma HIV-1 RNA level \<400 c/mL was obtained using FDA's snapshot algorithm, where all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) were treated as non-responders. Also, participants who switch their concomitant ART prior to the visit of interest as follows were also treated as non-responders: background ART substitutions not permitted per protocol; background ART substitutions permitted per protocol; however the decision to switch is not documented as being before or at the first On-treatment visit after switching to OBR (i.e. Day 28) where HIV-1 RNA is assessed.
Time frame: Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40 and 48
Absolute Values in Cluster of Differentiation 4+ (CD4+) Cell Counts Over Time
Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84.
Time frame: Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84
Median Change From Baseline in CD4+ Cell Counts Over Time
Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
Time frame: Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84
Absolute Values in Cluster of Differentiation 8+ (CD8+) Cell Counts Over Time
Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 28; and Weeks 12, 24, and 48.
Time frame: Baseline; Day 28; Weeks 12, 24, and 48
Median Change From Baseline in CD8+ Cell Counts Over Time
Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 28; and Weeks 12, 24, and 48. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
Time frame: Baseline; Day 28; Weeks 12, 24, and 48
Number of Participants With the Indicated Type of HIV-1 Disease Progression (Acquired Immunodeficiency Syndrome [AIDS] or Death [DT])
The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).
Time frame: From the day of the first dose of study drug until early withdrawal or the Week 48 analysis cut-off date (median of 55 study weeks)
Number of Participants With Any Adverse Event (Serious and Non-serious) of the Indicated Grade
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity; or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in other situations. Adverse events were graded for severity according to the Division of AIDS (DAIDS) toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).
Time frame: From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)
Number of Participants With the Maximum Post-Baseline-emergent Clinical Chemistry Toxicities of the Indicated Grade
Participants with post-Baseline-emergent clinical chemistry toxicities were analyzed. Clinical chemistry toxicities were graded for severity according to the DAIDS toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).
Time frame: From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)
Number of Participants With the Maximum Post-Baseline-emergent Hematology Toxicities of the Indicated Grade
Participants with post-Baseline-emergent hematology toxicities were analyzed. Hematology toxicities were graded for severity according to the DAIDS toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).
Time frame: From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)
AUC(0-tau) of DTG
The area under the time concentration curve over the dosing interval (AUC\[0-tau\]) of DTG was assessed by a population pharmacokinetic (PK) modeling approach using pooled DTG PK data from multiple studies. Blood samples for the determination of plasma DTG concentration were collected at the following time points: pre-dose and 1-3 hours post-dose on Day 8; pre-dose and within a post-dose window (1-3 hours or 4-12 hours) on Day 28 and Week 24. For Day 8 PK, only samples collected from participants randomized to the active DTG arm were analyzed.
Time frame: Day 8, Day 28, and Week 24
Cmax of DTG
The maximal concentration (Cmax) of DTG was assessed by a population PK modeling approach using pooled DTG PK data from multiple studies. Blood samples for the determination of plasma DTG concentration were collected at the following time points: pre-dose and 1-3 hours post-dose on Day 8; pre-dose and within a post-dose window (1-3 hours or 4-12 hours) on Day 28 and Week 24. For Day 8 PK, only samples collected from participants randomized to the active DTG arm were analyzed.
Time frame: Day 8, Day 28, and Week 24
Plasma DTG Pre-dose Concentration (C0) at Day 8, Day 28, and Week 24; and Average DTG C0 (C0 Avg) at Week 24
Blood samples for the determination of plasma DTG pre-dose concentration were collected pre-dose on Day 8, Day 28, and Week 24. For Day 8 PK, only samples collected from participants randomized to the active DTG arm were analyzed. C0 Avg was calculated at Week 24 as the mean of the concentration at Day 8, Day 28, and Week 24.
Time frame: Day 8, Day 28, and Week 24
Number of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance
For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Day 28, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>1 log10 copies/mL above the nadir value, where nadir is \>=400 copies/mL.Treatment-emergent IN mutations are those detected at the time of PDVF but not at Baseline.
Time frame: From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)
Number of Participants With the Indicated Fold Increase in Fold Change (FC) in the 50% Inhibitory Concentration Relative to Wild-type Virus for DTG (i.e. PDVF FC/Baseline FC Ratio) at the Time of PDVF, as a Measure of Phenotypic Resistance
For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF. The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Day 28, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>1 log10 copies/mL above the nadir value, where nadir is \>=400 copies/mL.
Time frame: From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)
Number of Participants Who Discontinued Study Treatment Due to AEs
The number of participants who permanently discontinued study treatment due to AEs is presented.
Time frame: From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)
Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
Twelve lead ECG was performed using an automated ECG machine. The number of participants with abnormal-clinically significant ECG findings at any time on-treatment is reported.
Time frame: Up to Week 24
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Vital signs including SBP and DBP were measured at Baseline, Week 24 and Week 48. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
Time frame: Baseline and Weeks 24 and 48
Change From Baseline in Heart Rate
Vital signs including heart rate was measured at Baseline, Week 24 and Week 48. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
Time frame: Baseline and Weeks 24 and 48
Change From Baseline in Albumin Level
Blood samples were collected for the analysis of clinical chemistry parameters such as albumin. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
Time frame: Baseline, Week 24 and 48
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Kinase
Blood samples were collected for the analysis of clinical chemistry parameters such as ALP, ALT, AST and creatine kinase. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Change From Baseline in Total Bilirubin (T. Bil) and Creatinine Levels
Blood samples were collected for the analysis of clinical chemistry parameters such as T. Bil and creatinine. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Change From Baseline in Cholesterol, Chloride, Carbon Dioxide (CO2)/Bicarbonate (HCO3), Glucose, High Density Lipoprotein Cholesterol, Potassium, Low Density Lipoprotein (LDL) Cholesterol, Sodium, Phosphorus, Triglycerides and Urea/Blood Urea Nitrogen
Blood samples were collected for the analysis of clinical chemistry parameters such as cholesterol, chloride, CO2/HCO3, glucose, high density lipoprotein (HDL) cholesterol, potassium, LDL cholesterol, sodium, phosphorus inorganic, triglycerides and urea/blood urea nitrogen (BUN). Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Change From Baseline in Creatinine Clearance
Creatinine clearance was calculated using Cockcroft-Gault formula. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
Time frame: Baseline, Day 8, Day 28, Week 8, Week 16, Week 24, Week 32 and Week 48
Change From Baseline in Lipase Levels
Blood samples were collected for the analysis of clinical chemistry parameters such as lipase level. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet and White Blood Cell (WBC) Count
Blood samples were collected for the analysis of hematology parameters such as basophils, eosinophils. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Change From Baseline in Hemoglobin Level
Blood samples were collected for the analysis of hematology parameters such as hemoglobin. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Change From Baseline in Hematocrit Level
Blood samples were collected for the analysis of hematology parameters such as hematocrit level. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Change From Baseline in Mean Corpuscle Volume
Blood samples were collected for the analysis of hematology parameters such as mean corpuscle volume. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Change From Baseline in Red Blood Cell Count
Blood samples were collected for the analysis of hematology parameters such as RBC. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
| Milestone | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Started | 14 | 16 |
| Completed | 14 | 16 |
| Not completed | 0 | 0 |
| Milestone | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Started | 13 | 16 |
| Completed | 7 | 13 |
| Not completed | 6 | 3 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Lack of efficacy | 4 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1) and Day 8. Change from Baseline was calculated as the value at Day 8 minus the value at Baseline (Day 1). The analysis was performed using statistical modeling correcting for Baseline plasma HIV-1 RNA, Baseline Dolutegravir (DTG) fold change (FC), the overall susceptibility score (OSS) of the failing regimen, and the interaction between DTG FC and treatment. Means and differences were calculated using the average Baseline DTG FC of the entire Intent-to-Treat Exposed (ITT-E) Population. The last observation carried forward with discontinuation equals Baseline (LOCFDB) dataset was used for the analysis. For the LOCFDB dataset, missing values were carried forward from the previous, non-missing, available on-treatment assessment, except formissing values due to premature withdrawal or Day 8 missing values, which had the Baseline value imputed.
| Log 10 copies per milliliter (c/mL) | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Mean Change From Baseline in Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) at Day 8 | -1.06 ± 0.168 | 0.10 ± 0.183 |
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Day 8, Day 28, Week 8, Week 12, Week 16, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, and Week 84. NA indicates data was not available.
| Log10 c/mL | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Baseline, n=14, 16 | 4.02 ± 0.940 | 4.42 ± 0.760 |
| Day 8, n=14, 16 | 2.95 ± 0.790 | 4.39 ± 0.844 |
| Day 28, n=13, 16 | 2.14 ± 0.772 | 2.30 ± 1.054 |
| Week 8, n=11, 16 | 2.35 ± 0.851 | 2.10 ± 0.913 |
| Week 12, n=12, 14 | 2.51 ± 1.048 | 2.27 ± 1.179 |
| Week 16, n=12, 16 | 2.57 ± 1.093 | 2.18 ± 1.098 |
| Week 24, n=11, 15 | 2.65 ± 1.219 | 1.88 ± 0.654 |
| Week 32, n=11, 14 | 2.72 ± 1.176 | 1.81 ± 0.664 |
| Week 40, n=7, 12 | 2.35 ± 1.169 | 1.68 ± 0.133 |
| Week 48, n=8, 13 | 2.47 ± 1.037 | 1.62 ± 0.088 |
| Week 60, n=5, 12 | 2.15 ± 1.013 | 1.67 ± 0.150 |
| Week 72, n=3, 4 | 2.35 ± 1.312 | 1.62 ± 0.054 |
| Week 84, n=0, 1 | — | 1.59 ± NA |
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Day 8, Day 28, Week 8, Week 12, Week 16, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, and Week 84. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
| Log10 c/mL | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Baseline, n=14, 16 | 4.02 ± 0.940 | 4.42 ± 0.760 |
| Day 8, n=14, 16 | -1.07 ± 0.683 | -0.03 ± 0.262 |
| Day 28, n=13, 16 | -1.87 ± 0.898 | -2.12 ± 1.111 |
| Week 8, n=11, 16 | -1.89 ± 0.890 | -2.32 ± 1.112 |
| Week 12, n=12, 14 | -1.54 ± 1.022 | -2.02 ± 1.245 |
| Week 16, n=12, 16 | -1.48 ± 1.101 | -2.24 ± 1.180 |
| Week 24, n=11, 15 | -1.38 ± 1.151 | -2.53 ± 1.033 |
| Week 32, n=11, 14 | -1.31 ± 1.059 | -2.62 ± 0.931 |
| Week 40, n=7, 12 | -1.48 ± 1.445 | -2.70 ± 0.843 |
| Week 48, n=8, 13 | -1.34 ± 1.235 | -2.77 ± 0.881 |
| Week 60, n=5, 12 | -1.91 ± 1.400 | -2.71 ± 0.863 |
| Week 72, n=3, 4 | -2.08 ± 1.311 | -3.31 ± 0.968 |
| Week 84, n=0, 1 | — | -3.75 ± NA |
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1); Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, and 48. Number of participants with plasma HIV-1 RNA level \<50 c/mL was obtained using Food and Drug Administration's (FDA's) snapshot algorithm, where all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) were treated as non-responders. Also, participants who switched their concomitant antiretroviral therapy (ART) prior to the visit of interest as follows were also treated as non-responders: background ART substitutions not permitted per protocol; background ART substitutions permitted per protocol; however, the decision to switch is not documented as being before or at the first On-treatment visit after switching to optimized background regimen (OBR) (i.e. Day 28) where HIV-1 RNA is assessed.
| Participants | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Baseline | 0 | 0 |
| Day 8 | 1 | 0 |
| Day 28 | 6 | 6 |
| Week 8 | 5 | 9 |
| Week 12 | 6 | 8 |
| Week 16 | 5 | 8 |
| Week 24 | 6 | 8 |
| Week 32 | 4 | 9 |
| Week 40 | 4 | 7 |
| Week 48 | 3 | 9 |
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1); Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40 and 48. Number of participants with plasma HIV-1 RNA level \<400 c/mL was obtained using FDA's snapshot algorithm, where all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) were treated as non-responders. Also, participants who switch their concomitant ART prior to the visit of interest as follows were also treated as non-responders: background ART substitutions not permitted per protocol; background ART substitutions permitted per protocol; however the decision to switch is not documented as being before or at the first On-treatment visit after switching to OBR (i.e. Day 28) where HIV-1 RNA is assessed.
| Participants | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Baseline | 2 | 0 |
| Day 8 | 4 | 0 |
| Day 28 | 9 | 12 |
| Week 8 | 7 | 13 |
| Week 12 | 7 | 10 |
| Week 16 | 7 | 12 |
| Week 24 | 6 | 11 |
| Week 32 | 6 | 10 |
| Week 40 | 5 | 10 |
| Week 48 | 6 | 10 |
Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84.
| Cells per cubic millimeters | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Baseline, n=14, 16 | 163.5 (111.0 to 231.0) | 90.5 (46.0 to 267.5) |
| Day 8, n=14, 15 | 198.5 (154.0 to 239.0) | 102.0 (50.0 to 310.0) |
| Day 28, n=13, 16 | 174.0 (168.0 to 335.0) | 234.0 (114.5 to 303.5) |
| Week 8, n=11, 16 | 211.0 (71.0 to 401.0) | 228.0 (124.0 to 357.5) |
| Week 12, n=12, 14 | 223.5 (115.0 to 345.5) | 217.5 (121.0 to 333.0) |
| Week 16, n=12, 16 | 241.0 (107.5 to 382.5) | 262.5 (132.5 to 436.5) |
| Week 24, n=11, 15 | 232.0 (116.0 to 509.0) | 242.0 (194.0 to 399.0) |
| Week 32, n=11, 14 | 213.0 (91.0 to 489.0) | 326.0 (229.0 to 542.0) |
| Week 40, n=8, 12 | 299.5 (212.5 to 566.5) | 328.0 (204.5 to 508.0) |
| Week 48, n=8, 13 | 328.0 (263.0 to 526.5) | 370.0 (231.0 to 457.0) |
| Week 60, n=5, 12 | 321.0 (234.0 to 328.0) | 333.0 (217.5 to 541.0) |
| Week 72, n=3, 4 | 321.0 (261.0 to 465.0) | 299.5 (231.5 to 349.0) |
| Week 84, n=0, 1 | — | 368.0 (368.0 to 368.0) |
Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
| Cells per cubic millimeters | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Baseline, n=14, 16 | 163.5 (111.0 to 231.0) | 90.5 (46.0 to 267.5) |
| Day 8, n=14, 15 | 7.0 (0.0 to 94.0) | 0.0 (-12.0 to 24.0) |
| Day 28, n=13, 16 | 14.0 (6.0 to 68.0) | 68.5 (5.0 to 140.5) |
| Week 8, n=11, 16 | 34.0 (10.0 to 96.0) | 87.5 (9.5 to 138.5) |
| Week 12, n=12, 14 | 49.0 (-5.0 to 83.0) | 79.0 (1.0 to 121.0) |
| Week 16, n=12, 16 | 76.5 (3.0 to 151.0) | 70.0 (20.5 to 235.0) |
| Week 24, n=11, 15 | 39.0 (0.0 to 134.0) | 117.0 (23.0 to 163.0) |
| Week 32, n=11, 14 | 48.0 (0.0 to 198.0) | 135.5 (58.0 to 271.0) |
| Week 40, n=8, 12 | 90.5 (45.0 to 226.5) | 125.5 (50.0 to 244.5) |
| Week 48, n=8, 13 | 115.0 (96.0 to 226.5) | 156.0 (68.0 to 293.0) |
| Week 60, n=5, 12 | 170.0 (65.0 to 210.0) | 146.0 (73.5 to 242.0) |
| Week 72, n=3, 4 | 163.0 (96.0 to 354.0) | 174.0 (147.0 to 225.0) |
| Week 84, n=0, 1 | — | 269.0 (269.0 to 269.0) |
Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 28; and Weeks 12, 24, and 48.
| Cells per cubic millimeter | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Baseline, n=14, 16 | 896.0 (589.0 to 1689.0) | 808.5 (436.5 to 1221.0) |
| Day 28, n=13, 16 | 1135.0 (598.0 to 1741.0) | 973.0 (675.0 to 1322.0) |
| Week 12, n=11, 14 | 1198.0 (591.0 to 1977.0) | 1184.0 (860.0 to 1711.0) |
| Week 24, n=11, 15 | 1160.0 (526.0 to 1908.0) | 1323.0 (969.0 to 1622.0) |
| Week 48, n=6, 12 | 1295.0 (837.0 to 1818.0) | 1147.0 (753.0 to 1570.0) |
Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 28; and Weeks 12, 24, and 48. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
| Cells per cubic millimeter | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Baseline, n=14, 16 | 896.0 (589.0 to 1689.0) | 808.5 (436.5 to 1221.0) |
| Day 28, n=13, 16 | 227.0 (-135.0 to 301.0) | 177.0 (51.0 to 278.5) |
| Week 12, n=11, 14 | 151.0 (-150.0 to 379.0) | 288.0 (193.0 to 484.0) |
| Week 24, n=11, 15 | 79.0 (-183.0 to 269.0) | 543.0 (35.0 to 930.0) |
| Week 48, n=6, 12 | 88.0 (-19.0 to 179.0) | 124.0 (-102.5 to 238.5) |
The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).
| Participants | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| From CDC Class A to CDC Class C | 0 | 0 |
| From CDC Class B to CDC Class C | 0 | 0 |
| From CDC Class C to new CDC Class C | 0 | 0 |
| From CDC Class A, B, or C to Death | 2 | 0 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity; or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in other situations. Adverse events were graded for severity according to the Division of AIDS (DAIDS) toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).
| Participants | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Grade 1 | 0 | 4 |
| Grade 2 | 7 | 6 |
| Grade 3 | 2 | 3 |
| Grade 4 | 2 | 1 |
Participants with post-Baseline-emergent clinical chemistry toxicities were analyzed. Clinical chemistry toxicities were graded for severity according to the DAIDS toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).
| Participants | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Grade 1 | 5 | 4 |
| Grade 2 | 5 | 5 |
| Grade 3 | 0 | 4 |
| Grade 4 | 0 | 1 |
Participants with post-Baseline-emergent hematology toxicities were analyzed. Hematology toxicities were graded for severity according to the DAIDS toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).
| Participants | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Grade 1 | 2 | 3 |
| Grade 2 | 2 | 5 |
| Grade 3 | 0 | 1 |
| Grade 4 | 0 | 0 |
The area under the time concentration curve over the dosing interval (AUC\[0-tau\]) of DTG was assessed by a population pharmacokinetic (PK) modeling approach using pooled DTG PK data from multiple studies. Blood samples for the determination of plasma DTG concentration were collected at the following time points: pre-dose and 1-3 hours post-dose on Day 8; pre-dose and within a post-dose window (1-3 hours or 4-12 hours) on Day 28 and Week 24. For Day 8 PK, only samples collected from participants randomized to the active DTG arm were analyzed.
| µg*hour per mL (µg*hr/mL) | Overall Study Arm |
|---|---|
| AUC(0-tau) of DTG | 37.9 ± 41.8 |
The maximal concentration (Cmax) of DTG was assessed by a population PK modeling approach using pooled DTG PK data from multiple studies. Blood samples for the determination of plasma DTG concentration were collected at the following time points: pre-dose and 1-3 hours post-dose on Day 8; pre-dose and within a post-dose window (1-3 hours or 4-12 hours) on Day 28 and Week 24. For Day 8 PK, only samples collected from participants randomized to the active DTG arm were analyzed.
| Micrograms per milliliter (µg/mL) | Overall Study Arm |
|---|---|
| Cmax of DTG | 4.14 ± 32.6 |
Blood samples for the determination of plasma DTG pre-dose concentration were collected pre-dose on Day 8, Day 28, and Week 24. For Day 8 PK, only samples collected from participants randomized to the active DTG arm were analyzed. C0 Avg was calculated at Week 24 as the mean of the concentration at Day 8, Day 28, and Week 24.
| µg/mL | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Day 8 C0, n=10, 0 | 3.043 ± 44 | — |
| Day 28 C0, n=11, 16 | 1.393 ± 189 | 2.154 ± 81 |
| Week 24 C0, n=10, 14 | 1.864 ± 110 | 2.201 ± 145 |
| C0_avg, n=13, 16 | 1.820 ± 188 | 2.307 ± 76 |
For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Day 28, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>1 log10 copies/mL above the nadir value, where nadir is \>=400 copies/mL.Treatment-emergent IN mutations are those detected at the time of PDVF but not at Baseline.
| Participants | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Any integrase mutation | 4 | 1 |
| L74L/M | 1 | 0 |
| T97A | 2 | 1 |
| E138E/K | 1 | 0 |
| E138K | 1 | 0 |
| S147G | 1 | 0 |
| N155N/H | 1 | 0 |
For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF. The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Day 28, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>1 log10 copies/mL above the nadir value, where nadir is \>=400 copies/mL.
| Participants | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| 4-<8 fold increase in DTG FC | 0 | 1 |
| >=8 fold increase in DTG FC | 4 | 0 |
The number of participants who permanently discontinued study treatment due to AEs is presented.
| Participants | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to AEs | 2 | 0 |
Twelve lead ECG was performed using an automated ECG machine. The number of participants with abnormal-clinically significant ECG findings at any time on-treatment is reported.
| Participants | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings | 1 | 1 |
Vital signs including SBP and DBP were measured at Baseline, Week 24 and Week 48. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
| millimeters of mercury | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| SBP; Baseline; n=14, 16 | 120.4 ± 15.60 | 113.4 ± 9.99 |
| SBP; Week 24; n=11, 15 | 2.0 ± 12.28 | 2.8 ± 13.82 |
| SBP; Week 48; n=6, 12 | -0.7 ± 19.50 | 3.1 ± 12.57 |
| DBP; Baseline; n=14, 16 | 78.9 ± 12.51 | 75.1 ± 8.46 |
| DBP; Week 24; n=11, 15 | -0.5 ± 9.49 | -1.2 ± 10.35 |
| DBP; Week 48; n=6, 12 | -1.2 ± 13.92 | -3.2 ± 8.78 |
Vital signs including heart rate was measured at Baseline, Week 24 and Week 48. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
| beats per minute | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Baseline; n=14, 16 | 72.5 ± 9.70 | 75.9 ± 14.56 |
| Week 24; n=11, 15 | -1.4 ± 8.42 | 0.7 ± 11.20 |
| Week 48; 6, 12 | 2.2 ± 11.03 | -2.5 ± 17.76 |
Blood samples were collected for the analysis of clinical chemistry parameters such as albumin. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
| grams per liter | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Albumin; Baseline; n=14, 16 | 43.1 ± 4.13 | 43.4 ± 3.88 |
| Albumin; Week 24; n=11, 15 | 0.0 ± 3.66 | 0.0 ± 3.87 |
| Albumin; Week 48; n=8, 13 | 1.3 ± 2.55 | -0.8 ± 3.69 |
Blood samples were collected for the analysis of clinical chemistry parameters such as ALP, ALT, AST and creatine kinase. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
| International units per liter | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| ALP; Baseline; n=14, 16 | 91.9 ± 29.64 | 114.9 ± 106.74 |
| ALP; Day 8; n=13, 15 | 1.9 ± 14.01 | -1.2 ± 9.41 |
| ALP; Day 28; n=13, 16 | -6.1 ± 10.71 | -0.6 ± 11.37 |
| ALP; Week 8; n=11, 16 | 1.6 ± 15.6 | 20.6 ± 63.97 |
| ALP; Week 12; n=12, 14 | -0.8 ± 10.19 | -0.3 ± 26.15 |
| ALP; Week 16; n=10, 16 | 3.1 ± 12.02 | 8.2 ± 40.55 |
| ALP; Week 24; n=11, 15 | 1.7 ± 21.72 | 3.3 ± 54.06 |
| ALP; Week 32; n=11, 14 | 6.9 ± 19.74 | 20.5 ± 35.89 |
| ALP; Week 40; n=8, 12 | 2.3 ± 20.26 | 7.8 ± 24.69 |
| ALP; Week 48; n=8, 13 | 28.0 ± 67.54 | 13.8 ± 32.07 |
| ALP; Week 60; n=5, 12 | 6.0 ± 23.86 | 12.8 ± 35.98 |
| ALP; Week 72; n=3, 4 | -5.0 ± 19.29 | 15.3 ± 10.21 |
| ALP; Week 84; n=0, 1 | — | 22.0 ± NA |
| ALT; Baseline; n=14, 16 | 24.9 ± 13.33 | 37.4 ± 22.70 |
| ALT; Day 8; n=13, 15 | 0.0 ± 7.02 | -3.8 ± 11.91 |
| ALT; Day 28; n=13, 16 | 0.4 ± 15.45 | -5.3 ± 23.65 |
| ALT; Week 8; n=11, 16 | 1.2 ± 20.30 | -9.2 ± 17.93 |
| ALT; Week 12; n=12, 14 | -5.4 ± 4.94 | -8.7 ± 23.36 |
| ALT; Week 16; n=10, 16 | -5.2 ± 3.97 | -10.1 ± 23.02 |
| ALT; Week 24; n=11, 15 | 3.1 ± 18.66 | -14.5 ± 23.16 |
| ALT; Week 32; n=11, 14 | 0.9 ± 14.01 | -10.6 ± 25.77 |
| ALT; Week 40; n=8, 12 | -1.6 ± 8.75 | -7.7 ± 25.86 |
| ALT; Week 48; n=8, 13 | 7.9 ± 20.02 | -9.2 ± 23.50 |
| ALT; Week 60; n=5, 12 | 0.8 ± 7.19 | -8.3 ± 24.28 |
| ALT; Week 72; n=3, 4 | 8.7 ± 17.67 | -29.3 ± 33.06 |
| ALT; Week 84; n=0, 1 | — | -3.0 ± NA |
| AST; Baseline; n=14, 16 | 28.9 ± 11.13 | 34.9 ± 14.35 |
| AST; Day 8; n=13, 15 | 1.0 ± 11.50 | -2.0 ± 9.17 |
| AST; Day 28; n=13, 16 | -4.0 ± 10.13 | -2.3 ± 17.08 |
| AST; Week 8; n=11, 16 | -2.9 ± 7.57 | -6.3 ± 9.64 |
| AST; Week 12; n=12, 14 | -4.8 ± 4.07 | -5.1 ± 11.78 |
| AST; Week 16; n=10, 16 | -4.0 ± 2.94 | -6.6 ± 12.27 |
| AST; Week 24; n=11, 15 | 1.7 ± 14.05 | -10.1 ± 11.87 |
| AST; Week 32; n=11, 14 | -1.7 ± 6.83 | -7.4 ± 13.14 |
| AST; Week 40; n=8, 12 | -4.9 ± 4.09 | -4.1 ± 12.46 |
| AST; Week 48; n=8, 13 | 9.0 ± 27.77 | -5.4 ± 10.47 |
| AST; Week 60; n=5, 12 | -3.2 ± 1.64 | -5.9 ± 9.24 |
| AST; Week 72; n=3, 4 | 1.3 ± 8.50 | -13.8 ± 12.31 |
| AST; Week 84; n=0, 1 | — | -8.0 ± NA |
| Creatine Kinase; Baseline; n=14, 16 | 162.4 ± 129.21 | 130.3 ± 76.46 |
| Creatine Kinase; Day 8; n=13, 15 | -2.1 ± 122.28 | -1.5 ± 53.29 |
| Creatine Kinase; Day 28; n=13, 16 | -35.6 ± 96.22 | 37.0 ± 123.10 |
| Creatine Kinase; Week 8; n=11, 16 | -16.4 ± 106.99 | -7.3 ± 68.19 |
| Creatine Kinase; Week 12; n=12, 14 | -18.8 ± 105.64 | 0.4 ± 84.85 |
| Creatine Kinase; Week 16; n=10, 16 | 34.2 ± 81.44 | 80.5 ± 305.19 |
| Creatine Kinase; Week 24; n=11, 15 | -24.4 ± 82.07 | -6.0 ± 67.29 |
| Creatine Kinase; Week 32; n=11, 14 | 2.3 ± 54.41 | 23.4 ± 96.88 |
| Creatine Kinase; Week 40; n=8, 12 | -50.0 ± 93.45 | 66.3 ± 168.54 |
| Creatine Kinase; Week 48; n=8, 13 | 7.8 ± 71.57 | 16.1 ± 68.96 |
| Creatine Kinase; Week 60; n=5, 12 | -12.2 ± 23.30 | 18.8 ± 86.19 |
| Creatine Kinase; Week 72; n=3, 4 | 35.0 ± 68.61 | -29.0 ± 76.27 |
| Creatine Kinase; Week 84; n=0, 1 | — | -134.0 ± NA |
Blood samples were collected for the analysis of clinical chemistry parameters such as T. Bil and creatinine. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
| Micromoles per liter | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| T. Bil.; Baseline; n=14, 16 | 10.0 ± 4.51 | 7.5 ± 3.14 |
| T. Bil.; Day 8; n=13, 15 | 0.8 ± 6.81 | -1.1 ± 2.12 |
| T. Bil.; Day 28; n=13, 16 | -0.2 ± 6.19 | 2.1 ± 9.78 |
| T. Bil.; Week 8; n=11, 16 | 0.0 ± 4.20 | 3.1 ± 13.76 |
| T. Bil.; Week 12; n=12, 14 | 0.5 ± 4.76 | -0.6 ± 2.14 |
| T. Bil.; Week 16; n=10, 16 | 0.6 ± 3.89 | 1.9 ± 10.89 |
| T. Bil.; Week 24; n=11, 15 | 0.2 ± 2.89 | 2.1 ± 8.19 |
| T. Bil.; Week 32; n=11, 14 | -0.4 ± 3.20 | 2.3 ± 10.16 |
| T. Bil.; Week 40; n=8, 12 | 0.0 ± 3.70 | 3.3 ± 12.43 |
| T. Bil.; Week 48; n=8, 13 | -0.8 ± 4.13 | 3.2 ± 12.18 |
| T. Bil.; Week 60; n=5, 12 | -2.4 ± 2.61 | 2.3 ± 11.63 |
| T. Bil.; Week 72; n=3, 4 | -1.3 ± 4.16 | 9.5 ± 16.36 |
| T. Bil.; Week 84; n=0, 1 | — | 2.0 ± NA |
| Creatinine; Baseline; n=14, 16 | 86.94 ± 18.971 | 88.96 ± 24.013 |
| Creatinine; Day 8; n=13, 15 | 10.96 ± 24.505 | 0.11 ± 14.873 |
| Creatinine; Day 28; n=13, 16 | 12.72 ± 19.697 | 13.58 ± 21.030 |
| Creatinine; Week 8; n=11, 16 | 12.15 ± 8.570 | 15.79 ± 19.574 |
| Creatinine; Week 12; n=12, 14 | 6.86 ± 9.153 | 9.85 ± 13.274 |
| Creatinine; Week 16; n=10, 16 | 8.22 ± 13.464 | 7.68 ± 13.031 |
| Creatinine; Week 24; n=11, 15 | 1.63 ± 11.098 | 13.31 ± 17.347 |
| Creatinine; Week 32; n=11, 14 | 0.98 ± 7.441 | 15.96 ± 11.902 |
| Creatinine; Week 40; n=8, 12 | 3.58 ± 10.788 | 12.94 ± 13.870 |
| Creatinine; Week 48; n=8, 13 | 4.21 ± 19.450 | 12.85 ± 9.128 |
| Creatinine; Week 60; n=5, 12 | 4.96 ± 5.560 | 11.72 ± 15.820 |
| Creatinine; Week 72; n=3, 4 | 0.93 ± 8.529 | 13.25 ± 16.957 |
| Creatinine; Week 84; n=0, 1 | — | 1.80 ± NA |
Blood samples were collected for the analysis of clinical chemistry parameters such as cholesterol, chloride, CO2/HCO3, glucose, high density lipoprotein (HDL) cholesterol, potassium, LDL cholesterol, sodium, phosphorus inorganic, triglycerides and urea/blood urea nitrogen (BUN). Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
| Millimoles per liter | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Cholesterol; Baseline; n=8, 10 | 3.819 ± 0.9219 | 4.725 ± 1.7430 |
| Cholesterol; Week 12; n=6, 8 | 0.433 ± 0.4622 | 0.538 ± 0.9598 |
| Cholesterol; Week 24; n=6, 10 | 0.308 ± 0.3137 | 0.585 ± 1.0296 |
| Cholesterol; Week 48; n=3, 7 | 0.567 ± 0.2021 | 0.421 ± 1.2770 |
| Cholesterol; Week 60; n=2, 5 | 0.375 ± 0.9546 | -0.020 ± 1.3326 |
| Cholesterol; Week 72; n=0, 1 | — | 1.350 ± NA |
| Chloride; Baseline; n=14, 16 | 104.1 ± 1.59 | 105.4 ± 3.32 |
| Chloride; Day 8; n=13, 15 | 0.5 ± 1.61 | 0.4 ± 2.03 |
| Chloride; Day 28; n=13, 16 | 0.4 ± 2.26 | -0.5 ± 2.58 |
| Chloride; Week 8; n=11, 16 | 0.5 ± 1.97 | -1.8 ± 3.08 |
| Chloride; Week 12; n=12, 14 | -0.8 ± 1.71 | 0.1 ± 2.73 |
| Chloride; Week 16; n=10, 16 | 1.4 ± 1.90 | -1.0 ± 2.73 |
| Chloride; Week 24; n=11, 15 | 0.9 ± 1.45 | -1.2 ± 3.14 |
| Chloride; Week 32; n=11, 14 | 1.1 ± 2.21 | 0.0 ± 2.57 |
| Chloride; Week 40; n=8, 12 | 0.5 ± 2.51 | 1.3 ± 2.80 |
| Chloride; Week 48; n=8, 13 | 1.5 ± 3.74 | -0.1 ± 3.38 |
| Chloride; Week 60; n=5, 12 | 2.0 ± 2.12 | 1.1 ± 2.81 |
| Chloride; Week 72; n=3, 4 | 2.0 ± 2.65 | 1.0 ± 2.94 |
| Chloride; Week 84; n=0, 1 | — | -2.0 ± NA |
| CO2/HCO3; Baseline; n=14, 16 | 22.5 ± 2.07 | 20.8 ± 4.12 |
| CO2/HCO3; Day 8; n=13, 15 | 0.2 ± 1.30 | 0.1 ± 2.25 |
| CO2/HCO3; Day 28; n=13, 16 | 0.4 ± 2.29 | 1.1 ± 2.47 |
| CO2/HCO3; Week 8; n=11, 16 | 1.2 ± 1.66 | 1.6 ± 3.40 |
| CO2/HCO3; Week 12; n=12, 14 | 1.7 ± 1.92 | 1.9 ± 2.73 |
| CO2/HCO3; Week 16; n=10, 16 | -0.2 ± 2.39 | 1.8 ± 3.42 |
| CO2/HCO3; Week 24; n=11, 15 | 0.9 ± 1.92 | 1.5 ± 2.92 |
| CO2/HCO3; Week 32; n=11, 14 | 1.5 ± 2.21 | 0.8 ± 2.69 |
| CO2/HCO3; Week 40; n=8, 12 | 0.9 ± 2.30 | -0.2 ± 2.25 |
| CO2/HCO3; Week 48; n=8, 13 | -0.4 ± 2.13 | 1.7 ± 3.01 |
| CO2/HCO3; Week 60; n=5, 12 | 0.8 ± 1.30 | 0.3 ± 2.42 |
| CO2/HCO3; Week 72; n=3, 4 | 2.0 ± 3.61 | -0.3 ± 1.89 |
| CO2/HCO3; Week 84; n=0, 1 | — | 4.0 ± NA |
| Glucose; Baseline; n=12, 16 | 4.84 ± 0.535 | 5.56 ± 1.994 |
| Glucose; Week 12; n=11, 14 | -0.01 ± 0.677 | 0.04 ± 0.679 |
| Glucose; Week 24; n=10, 15 | 0.17 ± 0.957 | -0.08 ± 1.024 |
| Glucose; Week 48; n=7, 13 | 0.13 ± 0.439 | 0.40 ± 1.143 |
| Glucose; Week 60; n=3, 12 | 0.20 ± 0.300 | -0.18 ± 0.723 |
| Glucose; Week 72; n=2, 4 | 0.45 ± 0.071 | 0.20 ± 0.744 |
| HDL Cholesterol; Baseline; n=8, 10 | 0.956 ± 0.2718 | 1.090 ± 0.2846 |
| HDL Cholesterol; Week 12; n=6, 8 | 0.117 ± 0.0683 | 0.156 ± 0.2485 |
| HDL Cholesterol; Week 24; n=6, 10 | 0.025 ± 0.1864 | 0.130 ± 0.2573 |
| HDL Cholesterol; Week 48; n=3, 7 | 0.117 ± 0.1155 | 0.136 ± 0.3363 |
| HDL Cholesterol; Week 60; n=2, 5 | -0.025 ± 0.0354 | 0.010 ± 0.3896 |
| HDL Cholesterol; Week 72; n=0, 1 | — | 0.350 ± NA |
| Potassium; Baseline; n=14, 16 | 4.16 ± 0.420 | 4.13 ± 0.377 |
| Potassium; Day 8; n=13, 15 | -0.09 ± 0.198 | -0.01 ± 0.301 |
| Potassium; Day 28; n=13, 16 | 0.19 ± 0.439 | 0.14 ± 0.518 |
| Potassium; Week 8; n=11, 16 | 0.12 ± 0.379 | 0.19 ± 0.421 |
| Potassium; Week 12; n=12, 14 | 0.03 ± 0.253 | 0.06 ± 0.373 |
| Potassium; Week 16; n=10, 16 | -0.06 ± 0.360 | -0.08 ± 0.556 |
| Potassium; Week 24; n=11, 15 | 0.17 ± 0.374 | 0.27 ± 0.641 |
| Potassium; Week 32; n=11, 14 | -0.04 ± 0.329 | 0.27 ± 0.327 |
| Potassium; Week 40; n=8, 12 | -0.01 ± 0.189 | 0.12 ± 0.259 |
| Potassium; Week 48; n=8, 13 | 0.15 ± 0.532 | 0.28 ± 0.508 |
| Potassium; Week 60; n=5, 12 | 0.06 ± 0.288 | 0.03 ± 0.614 |
| Potassium; Week 72; n=3, 4 | 0.37 ± 0.208 | 0.02 ± 0.512 |
| Potassium; Week 84; n=0, 1 | — | 0.20 ± NA |
| LDL Cholesterol; Baseline; n=8, 9 | 2.218 ± 0.9134 | 2.591 ± 1.3696 |
| LDL Cholesterol; Week 12; n=6, 8 | 0.293 ± 0.4197 | 0.500 ± 0.5145 |
| LDL Cholesterol; Week 24; n=6, 9 | 0.032 ± 0.5854 | 0.596 ± 0.7389 |
| LDL Cholesterol; Week 48; n=3, 6 | 0.330 ± 0.0458 | 0.322 ± 0.7725 |
| LDL Cholesterol; Week 60; n=2, 4 | 0.125 ± 0.5303 | -0.008 ± 1.0682 |
| LDL Cholesterol; Week 72; n=0, 1 | — | 1.110 ± NA |
| Sodium; Baseline; n=14, 16 | 138.8 ± 2.26 | 138.5 ± 2.22 |
| Sodium; Day 8; n=13, 15 | 0.2 ± 1.64 | -0.1 ± 2.02 |
| Sodium; Day 28; n=13, 16 | -0.2 ± 3.11 | -0.4 ± 2.60 |
| Sodium; Week 8; n=11, 16 | 0.2 ± 2.14 | -0.4 ± 2.03 |
| Sodium; Week 12; n=12, 14 | -0.5 ± 1.88 | 0.4 ± 2.53 |
| Sodium; Week 16; n=10, 16 | 1.3 ± 2.06 | 0.2 ± 1.94 |
| Sodium; Week 24; n=11, 15 | 0.5 ± 1.51 | -0.1 ± 2.33 |
| Sodium; Week 32; n=11, 14 | 0.8 ± 1.60 | 0.1 ± 1.41 |
| Sodium; Week 40; n=8, 12 | 1.0 ± 2.14 | 0.5 ± 1.57 |
| Sodium; Week 48; n=8, 13 | 0.9 ± 3.56 | 0.9 ± 2.40 |
| Sodium; Week 60; n=5, 12 | 2.4 ± 1.95 | 0.7 ± 2.46 |
| Sodium; Week 72; n=3, 4 | 1.3 ± 2.52 | 0.3 ± 1.50 |
| Sodium; Week 84; n=0, 1 | — | 0.0 ± NA |
| Phosphorus, inorganic; Baseline; n=14, 16 | 1.018 ± 0.1552 | 1.128 ± 0.1390 |
| Phosphorus, inorganic; Day 8; n=13, 15 | 0.012 ± 0.1261 | -0.123 ± 0.1635 |
| Phosphorus, inorganic; Day 28; n=13, 16 | 0.065 ± 0.2357 | -0.075 ± 0.1713 |
| Phosphorus, inorganic; Week 8; n=11, 16 | 0.018 ± 0.1722 | -0.075 ± 0.2244 |
| Phosphorus, inorganic; Week 12; n=12, 14 | 0.033 ± 0.1542 | -0.054 ± 0.1322 |
| Phosphorus, inorganic; Week 16; n=10, 16 | 0.080 ± 0.2263 | -0.053 ± 0.2617 |
| Phosphorus, inorganic; Week 24; n=11, 15 | -0.050 ± 0.1204 | -0.023 ± 0.1954 |
| Phosphorus, inorganic; Week 32; n=11, 14 | -0.036 ± 0.1343 | -0.050 ± 0.1787 |
| Phosphorus, inorganic; Week 40; n=8, 12 | 0.000 ± 0.1035 | -0.046 ± 0.2340 |
| Phosphorus, inorganic; Week 48; n=8, 13 | 0.025 ± 0.1282 | -0.031 ± 0.1331 |
| Phosphorus, inorganic; Week 60; n=5, 12 | 0.020 ± 0.1304 | -0.042 ± 0.1311 |
| Phosphorus, inorganic; Week 72; n=3, 4 | 0.017 ± 0.1258 | 0.013 ± 0.1031 |
| Phosphorus, inorganic; Week 84; n=0, 1 | — | 0.100 ± NA |
| Triglycerides; Baseline; n=8, 10 | 1.410 ± 0.5005 | 2.336 ± 1.1103 |
| Triglycerides; Week 12; n=6, 8 | 0.047 ± 0.6380 | -0.260 ± 1.1159 |
| Triglycerides; Week 24; n=6, 10 | 0.547 ± 0.9273 | -0.458 ± 1.2066 |
| Triglycerides; Week 48; n=3, 7 | 0.260 ± 0.3894 | -0.486 ± 1.3993 |
| Triglycerides; Week 60; n=2, 5 | 0.590 ± 0.8344 | -0.580 ± 1.0562 |
| Triglycerides; Week 72; n=0, 1 | — | -0.240 ± NA |
| Urea/BUN; Baseline; n=14, 16 | 5.64 ± 1.167 | 5.72 ± 2.324 |
| Urea/BUN; Day 8; n=13, 15 | 0.04 ± 1.233 | -0.43 ± 1.252 |
| Urea/BUN; Day 28; n=13, 16 | -0.23 ± 1.678 | -0.13 ± 1.875 |
| Urea/BUN; Week 8; n=11, 16 | -0.09 ± 1.200 | -0.59 ± 1.985 |
| Urea/BUN; Week 12; n=12, 14 | 0.25 ± 1.270 | -0.50 ± 1.676 |
| Urea/BUN; Week 16; n=10, 16 | -0.05 ± 1.787 | -1.00 ± 1.304 |
| Urea/BUN; Week 24; n=11, 15 | -0.09 ± 1.200 | -0.27 ± 1.841 |
| Urea/BUN; Week 32; n=11, 14 | -0.55 ± 1.150 | 0.57 ± 1.708 |
| Urea/BUN; Week 40; n=8, 12 | -0.19 ± 1.387 | 0.29 ± 1.339 |
| Urea/BUN; Week 48; n=8, 13 | 0.38 ± 1.157 | 0.88 ± 1.927 |
| Urea/BUN; Week 60; n=5, 12 | 0.30 ± 0.908 | 0.54 ± 1.888 |
| Urea/BUN; Week 72; n=3, 4 | 0.50 ± 0.500 | 0.50 ± 0.408 |
| Urea/BUN; Week 84; n=0, 1 | — | 0.00 ± NA |
Creatinine clearance was calculated using Cockcroft-Gault formula. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
| Milliliters per minute | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Baseline; n=14, 16 | 106.8 ± 31.79 | 104.8 ± 36.96 |
| Day 8; n=1, 0 | -13.0 ± NA | — |
| Day 28; n=13, 16 | -10.5 ± 13.06 | -10.4 ± 13.06 |
| Week 8; n=0, 1 | — | -12.0 ± NA |
| Week 16; n=10, 15 | -7.3 ± 12.00 | -12.5 ± 16.41 |
| Week 24; n=11, 15 | -2.3 ± 13.94 | -13.9 ± 17.38 |
| Week 32; n=9, 14 | -1.4 ± 8.82 | -16.0 ± 16.31 |
| Week 48; n=6, 12 | -6.8 ± 17.61 | -16.5 ± 14.34 |
Blood samples were collected for the analysis of clinical chemistry parameters such as lipase level. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
| Units per liter | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Lipase; Baseline; n=14, 16 | 29.1 ± 12.37 | 34.0 ± 18.54 |
| Lipase; Day 8; n=14, 15 | 3.4 ± 9.19 | 12.5 ± 32.97 |
| Lipase; Day 28; n=13, 16 | 3.3 ± 9.18 | 17.7 ± 63.64 |
| Lipase; Week 8; n=11, 16 | 2.6 ± 8.65 | 13.6 ± 42.89 |
| Lipase; Week 12; n=11, 14 | -2.4 ± 8.91 | 3.0 ± 19.24 |
| Lipase; Week 16; n=10, 16 | 7.6 ± 13.94 | -0.8 ± 12.90 |
| Lipase; Week 24; n=11, 15 | -2.7 ± 9.91 | 10.5 ± 29.18 |
| Lipase; Week 32; n=11, 14 | 0.8 ± 9.82 | 20.6 ± 49.70 |
| Lipase; Week 40; n=8, 12 | 0.6 ± 8.53 | 5.6 ± 19.78 |
| Lipase; Week 48; n=8, 13 | 3.8 ± 6.18 | 3.4 ± 16.05 |
| Lipase; Week 60; n=5, 12 | 5.0 ± 8.40 | 5.9 ± 22.01 |
| Lipase; Week 72; n=3, 4 | 16.0 ± 14.11 | 41.0 ± 94.20 |
| Lipase; Week 84; n=0, 1 | — | -9.0 ± NA |
Blood samples were collected for the analysis of hematology parameters such as basophils, eosinophils. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
| Giga cells per liter | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Basophils; Baseline; n=14, 16 | 0.016 ± 0.0122 | 0.015 ± 0.0126 |
| Basophils; Day 8; n=14, 15 | 0.006 ± 0.0134 | 0.002 ± 0.0094 |
| Basophils; Day 28; n=13, 16 | 0.005 ± 0.0176 | 0.004 ± 0.0222 |
| Basophils; Week 8; n=11, 16 | -0.001 ± 0.0122 | 0.004 ± 0.0120 |
| Basophils; Week 12; n=12, 14 | -0.001 ± 0.0144 | 0.000 ± 0.0124 |
| Basophils; Week 16; n=12, 16 | -0.002 ± 0.0147 | 0.005 ± 0.0137 |
| Basophils; Week 24; n=11, 15 | 0.001 ± 0.0158 | 0.007 ± 0.0188 |
| Basophils; Week 32; n=11, 13 | 0.002 ± 0.0108 | 0.005 ± 0.0185 |
| Basophils; Week 40; n=8, 12 | -0.000 ± 0.0207 | 0.003 ± 0.0144 |
| Basophils; Week 48; n=8, 13 | 0.006 ± 0.0130 | 0.008 ± 0.0174 |
| Basophils; Week 60; n=5, 12 | -0.002 ± 0.0164 | 0.004 ± 0.0173 |
| Basophils; Week 72; n=3, 4 | -0.003 ± 0.0153 | 0.008 ± 0.0275 |
| Basophils; Week 84; n=0, 1 | — | 0.010 ± NA |
| Eosinophils; Baseline; n=14, 16 | 0.087 ± 0.0935 | 0.158 ± 0.1681 |
| Eosinophils; Day 8; n=14, 15 | 0.016 ± 0.0388 | 0.005 ± 0.1076 |
| Eosinophils; Day 28; n=13, 16 | 0.023 ± 0.0253 | 0.033 ± 0.1939 |
| Eosinophils; Week 8; n=11, 16 | 0.041 ± 0.0561 | 0.090 ± 0.1464 |
| Eosinophils; Week 12; n=12, 14 | 0.023 ± 0.0492 | 0.240 ± 0.4390 |
| Eosinophils; Week 16; n=12, 16 | 0.024 ± 0.0887 | 0.141 ± 0.3009 |
| Eosinophils; Week 24; n=11, 15 | -0.003 ± 0.0987 | 0.159 ± 0.3737 |
| Eosinophils; Week 32; n=11, 13 | 0.016 ± 0.1108 | 0.075 ± 0.1921 |
| Eosinophils; Week 40; n=8, 12 | -0.015 ± 0.1285 | 0.011 ± 0.1054 |
| Eosinophils; Week 48; n=8, 13 | -0.028 ± 0.1241 | 0.122 ± 0.2186 |
| Eosinophils; Week 60; n=5, 12 | -0.038 ± 0.1392 | 0.098 ± 0.2143 |
| Eosinophils; Week 72; n=3, 4 | -0.043 ± 0.1185 | 0.053 ± 0.0660 |
| Eosinophils; Week 84; n=0, 1 | — | 0.240 ± NA |
| Lymphocytes; Baseline; n=14, 16 | 1.656 ± 0.9039 | 1.418 ± 0.7921 |
| Lymphocytes; Day 8; n=14, 15 | 0.165 ± 0.4910 | 0.040 ± 0.3262 |
| Lymphocytes; Day 28; n=13, 16 | 0.132 ± 0.4841 | 0.297 ± 0.3042 |
| Lymphocytes; Week 8; n=11, 16 | 0.490 ± 0.5591 | 0.536 ± 0.6238 |
| Lymphocytes; Week 12; n=12, 14 | 0.417 ± 0.9401 | 0.525 ± 0.4922 |
| Lymphocytes; Week 16; n=12, 16 | 0.554 ± 0.6402 | 0.594 ± 0.7014 |
| Lymphocytes; Week 24; n=11, 15 | 0.271 ± 0.7466 | 0.647 ± 0.8692 |
| Lymphocytes; Week 32; n=11, 13 | 0.173 ± 0.7166 | 0.818 ± 0.6910 |
| Lymphocytes; Week 40; n=8, 12 | 0.169 ± 0.6600 | 0.519 ± 0.6709 |
| Lymphocytes; Week 48; n=8, 13 | 0.474 ± 0.4207 | 0.563 ± 0.5703 |
| Lymphocytes; Week 60; n=5, 12 | 0.526 ± 0.3578 | 0.663 ± 0.6135 |
| Lymphocytes; Week 72; n=3, 4 | 0.673 ± 0.5327 | 0.623 ± 0.4280 |
| Lymphocytes; Week 84; n=0, 1 | — | 0.640 ± NA |
| Monocytes; Baseline; n=14, 16 | 0.367 ± 0.2075 | 0.306 ± 0.1117 |
| Monocytes; Day 8; n=14, 15 | 0.003 ± 0.2379 | 0.027 ± 0.1460 |
| Monocytes; Day 28; n=13, 16 | -0.042 ± 0.1999 | 0.031 ± 0.1196 |
| Monocytes; Week 8; n=11, 16 | -0.022 ± 0.1256 | 0.037 ± 0.1111 |
| Monocytes; Week 12; n=12, 14 | -0.053 ± 0.1215 | 0.065 ± 0.1075 |
| Monocytes; Week 16; n=12, 16 | -0.027 ± 0.1262 | 0.089 ± 0.1430 |
| Monocytes; Week 24; n=11, 15 | -0.067 ± 0.1152 | 0.017 ± 0.1716 |
| Monocytes; Week 32; n=11, 13 | -0.059 ± 0.1208 | 0.017 ± 0.1616 |
| Monocytes; Week 40; n=8, 12 | -0.030 ± 0.0685 | 0.011 ± 0.0983 |
| Monocytes; Week 48; n=8, 13 | -0.050 ± 0.1598 | 0.018 ± 0.0985 |
| Monocytes; Week 60; n=5, 12 | -0.088 ± 0.1359 | -0.003 ± 0.1305 |
| Monocytes; Week 72; n=3, 4 | 0.003 ± 0.0987 | 0.055 ± 0.1196 |
| Monocytes; Week 84; n=0, 1 | — | -0.230 ± NA |
| Total neutrophils; Baseline; n=14, 16 | 2.327 ± 1.2068 | 1.869 ± 1.0565 |
| Total neutrophils; Day 8; n=14, 15 | 0.090 ± 0.9029 | 0.072 ± 0.6338 |
| Total neutrophils; Day 28; n=13, 16 | 0.196 ± 0.7017 | 0.659 ± 0.9376 |
| Total neutrophils; Week 8; n=11, 16 | 0.480 ± 0.7919 | 0.344 ± 0.7325 |
| Total neutrophils; Week 12; n=12, 14 | 0.022 ± 0.5946 | 0.357 ± 0.5410 |
| Total neutrophils; Week 16; n=12, 16 | 0.780 ± 1.7187 | 1.030 ± 0.7759 |
| Total neutrophils; Week 24; n=11, 15 | -0.128 ± 0.7851 | 0.746 ± 1.3053 |
| Total neutrophils; Week 32; n=11, 13 | 0.213 ± 0.9525 | 0.875 ± 1.0945 |
| Total neutrophils; Week 40; n=8, 12 | 0.224 ± 1.0274 | 0.390 ± 0.4501 |
| Total neutrophils; Week 48; n=8, 13 | 0.144 ± 0.5807 | 0.986 ± 1.0983 |
| Total neutrophils; Week 60; n=5, 12 | 0.162 ± 0.7959 | 1.507 ± 1.7191 |
| Total neutrophils; Week 72; n=3, 4 | 0.783 ± 1.6101 | 2.363 ± 2.0072 |
| Total neutrophils; Week 84; n=0, 1 | — | 2.060 ± NA |
| Platelet; Baseline; n=14, 16 | 173.0 ± 65.30 | 176.9 ± 56.97 |
| Platelet; Day 8; n=14, 15 | 21.6 ± 29.23 | 16.5 ± 29.08 |
| Platelet; Day 28; n=13, 16 | 33.9 ± 29.87 | 30.8 ± 43.76 |
| Platelet; Week 8; n=11, 16 | 57.8 ± 70.86 | 29.1 ± 57.51 |
| Platelet; Week 12; n=12, 14 | 36.5 ± 33.68 | 39.2 ± 56.51 |
| Platelet; Week 16; n=12, 16 | 35.7 ± 39.58 | 52.6 ± 56.43 |
| Platelet; Week 24; n=11, 15 | 33.5 ± 31.41 | 58.7 ± 64.10 |
| Platelet; Week 32; n=11, 13 | 12.1 ± 33.87 | 55.6 ± 74.60 |
| Platelet; Week 40; n=8, 12 | 25.6 ± 38.38 | 44.9 ± 48.17 |
| Platelet; Week 48; n=8, 13 | 24.6 ± 36.49 | 53.5 ± 63.73 |
| Platelet; Week 60; n=5, 12 | 43.0 ± 18.36 | 51.5 ± 58.12 |
| Platelet; Week 72; n=3, 4 | 34.3 ± 40.15 | 64.0 ± 94.89 |
| Platelet; Week 84; n=0, 1 | — | 88.0 ± NA |
| WBC; Baseline; n=14, 16 | 4.44 ± 1.752 | 3.78 ± 1.522 |
| WBC; Day 8; n=14, 15 | 0.29 ± 1.082 | 0.15 ± 0.890 |
| WBC; Day 28; n=13, 16 | 0.33 ± 0.946 | 1.03 ± 1.105 |
| WBC; Week 8; n=11, 16 | 1.00 ± 1.015 | 1.02 ± 1.008 |
| WBC; Week 12; n=12, 14 | 0.42 ± 1.192 | 1.19 ± 1.005 |
| WBC; Week 16; n=12, 16 | 1.36 ± 2.050 | 1.86 ± 1.398 |
| WBC; Week 24; n=11, 15 | 0.09 ± 1.276 | 1.59 ± 2.075 |
| WBC; Week 32; n=11, 13 | 0.35 ± 1.264 | 1.78 ± 1.600 |
| WBC; Week 40; n=8, 12 | 0.36 ± 1.162 | 0.93 ± 0.965 |
| WBC; Week 48; n=8, 13 | 0.56 ± 0.655 | 1.70 ± 1.480 |
| WBC; Week 60; n=5, 12 | 0.58 ± 0.973 | 2.25 ± 1.579 |
| WBC; Week 72; n=3, 4 | 1.43 ± 1.210 | 3.10 ± 2.349 |
| WBC; Week 84; n=0, 1 | — | 2.70 ± NA |
Blood samples were collected for the analysis of hematology parameters such as hemoglobin. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
| Grams per liter | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Baseline; n=14, 16 | 132.9 ± 16.16 | 129.9 ± 21.08 |
| Day 8; n=14, 15 | -1.0 ± 6.98 | -1.3 ± 4.37 |
| Day 28; n=13, 16 | -2.5 ± 8.76 | -0.9 ± 9.62 |
| Week 8; n=11, 16 | -4.5 ± 13.71 | 2.6 ± 12.48 |
| Week 12; n=12, 14 | -1.0 ± 12.59 | 2.1 ± 11.02 |
| Week 16; n=12 16 | 0.0 ± 15.47 | 1.9 ± 10.14 |
| Week 24; n=11, 15 | -0.6 ± 10.60 | 1.5 ± 8.82 |
| Week 32; n=11, 13 | -2.4 ± 10.66 | 1.5 ± 9.49 |
| Week 40; n=8, 12 | -0.9 ± 12.14 | 0.7 ± 11.32 |
| Week 48; n=8, 13 | 0.0 ± 9.80 | 0.5 ± 13.48 |
| Week 60; n=5, 12 | -1.8 ± 13.99 | 5.0 ± 13.22 |
| Week 72; n=3, 4 | -4.3 ± 7.37 | 7.0 ± 8.72 |
| Week 84; n=0, 1 | — | -6.0 ± NA |
Blood samples were collected for the analysis of hematology parameters such as hematocrit level. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
| Proportion of red blood cells in blood | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Baseline; n=14, 16 | 0.4024 ± 0.05259 | 0.3974 ± 0.06496 |
| Day 8; n=14, 15 | -0.0015 ± 0.02666 | -0.0049 ± 0.01515 |
| Day 28; n=13, 16 | -0.0066 ± 0.03105 | -0.0043 ± 0.03313 |
| Week 8; n=11, 16 | -0.0105 ± 0.04383 | 0.0092 ± 0.04092 |
| Week 12; n=12, 14 | -0.0027 ± 0.03702 | 0.0054 ± 0.03419 |
| Week 16; n=12, 16 | -0.0033 ± 0.04275 | 0.0021 ± 0.03054 |
| Week 24; n=11, 15 | -0.0025 ± 0.03707 | 0.0062 ± 0.02787 |
| Week 32; n=11, 13 | -0.0081 ± 0.03310 | 0.0062 ± 0.03144 |
| Week 40; n=8, 12 | -0.0005 ± 0.03257 | 0.0063 ± 0.03601 |
| Week 48; n=8, 13 | 0.0065 ± 0.02919 | 0.0078 ± 0.04331 |
| Week 60; n=5, 12 | -0.0024 ± 0.04000 | 0.0200 ± 0.04520 |
| Week 72; n=3, 4 | -0.0170 ± 0.03119 | 0.0248 ± 0.02943 |
| Week 84; n=0, 1 | — | -0.0090 ± NA |
Blood samples were collected for the analysis of hematology parameters such as mean corpuscle volume. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
| Femtoliter | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Baseline; n=14, 16 | 99.1 ± 8.83 | 97.8 ± 9.28 |
| Day 8; n=14, 15 | 0.1 ± 2.35 | 0.3 ± 1.71 |
| Day 28; n=13, 16 | 1.2 ± 3.26 | 0.3 ± 3.82 |
| Week 8; n=11, 16 | 0.3 ± 3.77 | -0.3 ± 6.02 |
| Week 12; n=12, 14 | 1.1 ± 7.73 | -1.5 ± 7.39 |
| Week 16; n=12, 16 | 0.3 ± 7.84 | -2.2 ± 8.85 |
| Week 24; n=11, 15 | -0.3 ± 8.25 | -2.0 ± 10.36 |
| Week 32; n=11, 13 | -1.0 ± 8.54 | -2.4 ± 10.87 |
| Week 40; n=8, 12 | 2.5 ± 8.75 | -0.7 ± 11.41 |
| Week 48; n=8, 13 | 2.0 ± 7.76 | -1.0 ± 11.73 |
| Week 60; n=5, 12 | 1.4 ± 7.89 | -1.2 ± 11.82 |
| Week 72; n=3, 4 | 0.3 ± 10.12 | 2.3 ± 14.10 |
| Week 84; n=0, 1 | — | 18.0 ± NA |
Blood samples were collected for the analysis of hematology parameters such as RBC. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.
| Trillion cells per liter | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Baseline; n=14, 16 | 4.09 ± 0.550 | 4.09 ± 0.731 |
| Day 8; n=14, 15 | 0.00 ± 0.254 | -0.04 ± 0.140 |
| Day 28; n=13, 16 | -0.08 ± 0.309 | -0.06 ± 0.318 |
| Week 8; n=11, 16 | -0.14 ± 0.434 | 0.12 ± 0.435 |
| Week 12; n=12, 14 | -0.05 ± 0.493 | 0.15 ± 0.477 |
| Week 16; n=12, 16 | -0.03 ± 0.529 | 0.13 ± 0.478 |
| Week 24; n=11, 15 | 0.02 ± 0.464 | 0.18 ± 0.514 |
| Week 32; n=11, 13 | -0.04 ± 0.467 | 0.18 ± 0.504 |
| Week 40; n=8, 12 | -0.08 ± 0.392 | 0.09 ± 0.658 |
| Week 48; n=8, 13 | -0.00 ± 0.334 | 0.15 ± 0.625 |
| Week 60; n=5, 12 | -0.06 ± 0.428 | 0.28 ± 0.625 |
| Week 72; n=3, 4 | -0.20 ± 0.173 | 0.25 ± 0.759 |
| Week 84; n=0, 1 | — | -0.60 ± NA |
Collected over Serious adverse events (SAEs) and non-serious AEs were collected in the time period from the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DTG 50mg BID | 2/14 (14.3%) | 5/14 (35.7%) | 11/14 (78.6%) |
| Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase | 0/16 (0%) | 4/16 (25%) | 14/16 (87.5%) |
| Event | DTG 50mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| Coronary artery diseaseCardiac disorders | 1/14 | 0/16 |
| DiarrhoeaGastrointestinal disorders | 1/14 | 0/16 |
| Cardiac deathGeneral disorders | 1/14 | 0/16 |
| Renal failure acuteRenal and urinary disorders | 1/14 | 0/16 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/14 | 0/16 |
| Cardiac arrestCardiac disorders | 1/14 | 0/16 |
| Chest painGeneral disorders | 1/14 | 0/16 |
| PneumoniaInfections and infestations | 1/14 | 0/16 |
| Multiple fracturesInjury, poisoning and procedural complications | 0/14 | 1/16 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/14 | 1/16 |
| Event | DTG 50mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/14 | 2/16 |
| HeadacheNervous system disorders | 3/14 | 1/16 |
| NauseaGastrointestinal disorders | 3/14 | 2/16 |
| LymphadenopathyBlood and lymphatic system disorders | 3/14 | 0/16 |
| Upper respiratory tract infectionInfections and infestations | 1/14 | 3/16 |
| DepressionPsychiatric disorders | 1/14 | 3/16 |
| Abdominal pain upperGastrointestinal disorders | 2/14 | 0/16 |
| DizzinessNervous system disorders | 2/14 | 0/16 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/14 | 1/16 |
| Chest painGeneral disorders | 2/14 | 0/16 |
| Age, Continuous(Years) | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase | Total |
|---|---|---|---|
| Mean | 47.5 ± 11.56 | 48.6 ± 8.85 | 48.1 ± 10.04 |
| Sex: Female, Male(Participants) | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase | Total |
|---|---|---|---|
| Female | 2 | 4 | 6 |
| Male | 12 | 12 | 24 |
| Race/Ethnicity, Customized(Participants) | DTG 50 mg BID | Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase | Total |
|---|---|---|---|
| African American/African Heritage | 8 | 8 | 16 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| White - Arabic/North African Heritage | 1 | 0 | 1 |
| White - White/Caucasian/European Heritage | 4 | 7 | 11 |
| Missing: None of the Available Races Applied | 1 | 0 | 1 |
Ran from Apr 2012 to primary completion in Oct 2012, 6 months.
Results were first posted in Feb 2014, 1 year 3 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 6 months is below that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dolutegravir